Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Schott

Cardiovascular Disease Royal Oak, MI Doctor of Osteopathy

NPI 1942628748 CMS profile 4227871

3601 W 13 Mile Rd, Royal Oak, MI 48073

Open in the dashboard

General payments

$24,970

209 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Schott of Royal Oak, MI is reported in the CMS Open Payments database as having received $24,970 across 209 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $598 24
2024 General $954 44
2023 General $1,938 61
2022 General $3,427 48
2021 General $18,001 29
2020 General $37 2
2019 General $15 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Schott
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Jason Schott were reported at $598. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Jason Schott Cardiovascular Disease median Middle half National median
2019 $15 $450 $127–$1,392 $163
2020 $37 $242 $77–$751 $114
2021 $18,001 $335 $101–$1,037 $132
2022 $3,427 $395 $121–$1,211 $149
2023 $1,938 $443 $136–$1,283 $160
2024 $954 $450 $136–$1,323 $164
2025 $598 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $13,523 38 payments
  2. Abbott Laboratories $5,042 3 payments
  3. Edwards Lifesciences Corporation $2,776 33 payments
  4. Boston Scientific Corporation $1,304 45 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $441 24 payments
  6. Abiomed $345 4 payments
  7. Cardiva Medical, Inc. $259 6 payments
  8. E.R. Squibb & Sons, L.L.C. $185 11 payments
  9. Janssen Pharmaceuticals, Inc $176 5 payments
  10. Inari Medical, Inc. $171 3 payments
  11. Other $747 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $16,000 2 payments
  2. Food and Beverage $5,960 192 payments
  3. Travel and Lodging $2,856 12 payments
  4. Education $154 3 payments
Products named General payments · program years 2019–2025
  1. CoreValve Evolut $12,507 15 payments
  2. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $1,389 16 payments
  3. COREVALVE EVOLUT R $904 18 payments
  4. LifeVest $441 24 payments
  5. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $358 16 payments
  6. Impella $345 4 payments
  7. FLOWTRIEVER CATHETER, S $342 6 payments
  8. AVVIGO Guidance System $270 11 payments
  9. WATCHMAN FLX $206 6 payments
  10. Cardiva VASCADE MVP VVCS 6-12F $189 3 payments
  11. Other $2,335 103 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

2,449

Median for Interventional Radiology: 38

Drug cost

$201,020

Median for Interventional Radiology: $333

Branded share of claims

30.6%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 144 $114,643
Brilinta Ticagrelor Brand 33 $23,026
Repatha Sureclick Evolocumab Brand 30 $20,192
Xarelto Rivaroxaban Brand 14 $15,908
Jardiance Empagliflozin Brand 13 $8,785
Clopidogrel Clopidogrel Bisulfate Brand 433 $3,471
Rosuvastatin Calcium Generic 385 $3,350
Metoprolol Succinate Generic 243 $1,835
Ranolazine Er Ranolazine Brand 17 $1,326
Bumetanide Generic 28 $1,087

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$110,538

Medicare's payments for the services billed

Medicare patients

321

Average age 75

Services billed

967

154 women, 167 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Arthritis 60%
Heart failure 45%
Diabetes 43%
Atrial fibrillation 39%
Chronic kidney disease 35%
COPD 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $88
  • PFIZER INC. $9
$97 144 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $58
$58 — —
Repatha
  • Amgen Inc. $56
$56 30 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $27
$27 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

209 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record